The Respiratory Illness Live Virus Fill / Finish Services Master IDIQ, issued by the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services, focuses on establishing medical countermeasure manufacturing capabilities for live virus and vectored vaccine products. The contract vehicle aims to support the development of critical medical countermeasures, specifically targeting the fill and finish manufacturing processes necessary for advancing vaccine and viral product candidates towards regulatory licensure. This IDIQ provides a framework for multiple prime contractors to execute specialized biotechnology and pharmaceutical manufacturing services related to respiratory illness medical countermeasures.
Task orders under this contract vehicle likely involve complex biomanufacturing services, with typical values potentially ranging from $500,000 to $10 million and durations spanning 12-36 months. The primary funding source is BARDA, which is known for supporting pandemic preparedness and medical countermeasure development. Contractors would be expected to have advanced Good Manufacturing Practice (GMP) facilities capable of handling live viruses and producing vaccine/viral vector products, with performance locations predominantly situated in biosafety level 2 or 3 laboratory and manufacturing environments. Prime contractors would likely include specialized biotechnology contract development and manufacturing organizations (CDMOs) with expertise in viral vector production, vaccine fill/finish processes, and regulatory compliance for medical countermeasure development.